Literature DB >> 23481459

N-ethylmaleimide activates a Cl(-)-independent component of K(+) flux in mouse erythrocytes.

Boris E Shmukler1, Ann Hsu, Jessica Alves, Marie Trudel, Marco B Rust, Christian A Hubner, Alicia Rivera, Seth L Alper.   

Abstract

The K-Cl cotransporters (KCCs) of mouse erythrocytes exhibit higher basal activity than those of human erythrocytes, but are similarly activated by cell swelling, by hypertonic urea, and by staurosporine. However, the dramatic stimulation of human erythroid KCCs by N-ethylmaleimide (NEM) is obscured in mouse erythrocytes by a prominent NEM-stimulated K(+) efflux that lacks Cl(-)-dependence. The NEM-sensitivity of Cl(-)-independent K(+) efflux of mouse erythrocytes is lower than that of KCC. The genetically engineered absence of the K-Cl cotransporters KCC3 and KCC1 from mouse erythrocytes does not modify Cl(-)-independent K(+) efflux. Mouse erythrocytes genetically devoid of the Gardos channel KCNN4 show increased NEM-sensitivity of both Cl(-)-independent K(+) efflux and K-Cl cotransport. The increased NEM-sensitivity and stimulation magnitude of Cl(-)-independent K(+) efflux in mouse erythrocytes expressing transgenic hypersickling human hemoglobin SAD (HbSAD) are independent of the presence of KCC3 and KCC1, but absence of KCNN4 reduces the stimulatory effect of HbSAD. NEM-stimulated Cl(-)-independent K(+) efflux of mouse red cells is insensitive to ouabain and bumetanide, but partially inhibited by chloroquine, barium, and amiloride. The NEM-stimulated activity is modestly reduced at pH6.0 but not significantly altered at pH8.0, and is abolished at 0°C. Although the molecular identity of this little-studied K(+) efflux pathway of mouse erythrocytes remains unknown, its potential role in the pathophysiology of sickle red cell dehydration will be important for the extrapolation of studies in mouse models of sickle cell disease to our understanding of humans with sickle cell anemia.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23481459      PMCID: PMC3646938          DOI: 10.1016/j.bcmd.2013.02.004

Source DB:  PubMed          Journal:  Blood Cells Mol Dis        ISSN: 1079-9796            Impact factor:   3.039


  65 in total

Review 1.  Ion transport pathology in the mechanism of sickle cell dehydration.

Authors:  Virgilio L Lew; Robert M Bookchin
Journal:  Physiol Rev       Date:  2005-01       Impact factor: 37.312

2.  Inhibition by divalent cations and sulphydryl reagents of the passive Ca2+ transport in human red blood cells observed in the presence of vanadate.

Authors:  L Varecka; E Peterajová; J Pogády
Journal:  Biochim Biophys Acta       Date:  1986-04-25

Review 3.  A potent oral P-selectin blocking agent improves microcirculatory blood flow and a marker of endothelial cell injury in patients with sickle cell disease.

Authors:  Abdullah Kutlar; Kenneth I Ataga; Lillian McMahon; Joanna Howard; Frederic Galacteros; Ward Hagar; Elliott Vichinsky; Anthony T W Cheung; Neil Matsui; Stephen H Embury
Journal:  Am J Hematol       Date:  2012-04-10       Impact factor: 10.047

4.  Mouse models for studying pain in sickle disease: effects of strain, age, and acuteness.

Authors:  David M Cain; Derek Vang; Donald A Simone; Robert P Hebbel; Kalpna Gupta
Journal:  Br J Haematol       Date:  2011-12-15       Impact factor: 6.998

5.  Effect of peroxynitrite on passive K+ transport in human red blood cells.

Authors:  Yuliya Kucherenko; Joseph Browning; Amanda Tattersall; J Clive Ellory; John S Gibson
Journal:  Cell Physiol Biochem       Date:  2005

6.  Prooxidant activity and cellular effects of the phenoxyl radicals of dietary flavonoids and other polyphenolics.

Authors:  Giuseppe Galati; Omid Sabzevari; John X Wilson; Peter J O'Brien
Journal:  Toxicology       Date:  2002-08-01       Impact factor: 4.221

7.  Physiological roles of the intermediate conductance, Ca2+-activated potassium channel Kcnn4.

Authors:  Ted Begenisich; Tesuji Nakamoto; Catherine E Ovitt; Keith Nehrke; Carlo Brugnara; Seth L Alper; James E Melvin
Journal:  J Biol Chem       Date:  2004-09-03       Impact factor: 5.157

8.  Therapy with oral clotrimazole induces inhibition of the Gardos channel and reduction of erythrocyte dehydration in patients with sickle cell disease.

Authors:  C Brugnara; B Gee; C C Armsby; S Kurth; M Sakamoto; N Rifai; S L Alper; O S Platt
Journal:  J Clin Invest       Date:  1996-03-01       Impact factor: 14.808

9.  Modulation of Ca2+ channels by PTX-sensitive G-proteins is blocked by N-ethylmaleimide in rat sympathetic neurons.

Authors:  M S Shapiro; L P Wollmuth; B Hille
Journal:  J Neurosci       Date:  1994-11       Impact factor: 6.167

10.  Activation of electroneutral K flux in Amphiuma red blood cells by N-ethylmaleimide. Distinction between K/H exchange and KCl cotransport.

Authors:  J S Adorante; P M Cala
Journal:  J Gen Physiol       Date:  1987-08       Impact factor: 4.086

View more
  3 in total

1.  The erythroid K-Cl cotransport inhibitor [(dihydroindenyl)oxy]acetic acid blocks erythroid Ca2+-activated K+ channel KCNN4.

Authors:  Alicia Rivera; Joshua A Nasburg; Heesung Shim; Boris E Shmukler; Jason Kitten; Jay G Wohlgemuth; Jeffrey S Dlott; L Michael Snyder; Carlo Brugnara; Heike Wulff; Seth L Alper
Journal:  Am J Physiol Cell Physiol       Date:  2022-07-18       Impact factor: 5.282

2.  The Clinically Tested Gardos Channel Inhibitor Senicapoc Exhibits Antimalarial Activity.

Authors:  Venée N Tubman; Pedro Mejia; Boris E Shmukler; Amy K Bei; Seth L Alper; James R Mitchell; Carlo Brugnara; Manoj T Duraisingh
Journal:  Antimicrob Agents Chemother       Date:  2015-10-12       Impact factor: 5.191

3.  Genetic disruption of KCC cotransporters in a mouse model of thalassemia intermedia.

Authors:  Boris E Shmukler; Alicia Rivera; Parul Bhargava; Katherine Nishimura; Edward H Kim; Ann Hsu; Jay G Wohlgemuth; James Morton; L Michael Snyder; Lucia De Franceschi; Marco B Rust; Christian A Hubner; Carlo Brugnara; Seth L Alper
Journal:  Blood Cells Mol Dis       Date:  2019-11-25       Impact factor: 3.039

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.